TL;DR
High-intensity focused ultrasound (HIFU) shows promise as a salvage treatment for cervical cancer patients with residual or recurrent disease after chemoradiotherapy (CRT). This non-invasive approach achieved a high disease control rate and extended survival, offering a safer alternative to traditional salvage therapies like surgery.
What Problem Does This Paper Address?
Cervical cancer, a significant global health concern, often presents challenges in treatment, particularly for patients with locally advanced disease. While chemoradiotherapy (CRT) is a standard treatment, a substantial portion of patients (30-65%) experience residual disease or recurrence after CRT. Treating these cases is difficult because the previously irradiated area limits the effectiveness and safety of further radiation or surgery. Salvage surgery and re-irradiation, while options, are often traumatic and associated with limited efficacy and significant complications. This leaves a critical need for effective, less invasive local treatment options for these patients.
Methods
This study retrospectively analyzed data from 153 cervical cancer patients who underwent High-Intensity Focused Ultrasound (HIFU) treatment between 2010 and 2021 for residual or recurrent disease within a previously irradiated field. HIFU, a non-invasive technique, uses focused ultrasound energy to ablate tumor tissue while minimizing damage to surrounding healthy tissue. The treatment involved a high-intensity focused tumor therapy system with real-time ultrasound guidance. Therapeutic parameters were adjusted for each patient. Efficacy was evaluated using RECIST criteria, and survival outcomes (progression-free survival - PFS, and overall survival - OS) were assessed. Adverse effects were categorized using the Society of Interventional Radiology (SIR) Classification System.
Datasets
The study utilized data from 153 cervical cancer patients treated at the Guizhou Provincial People's Hospital between January 2010 and January 2021. This retrospective analysis included clinicopathological data and treatment details. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- HIFU as a Viable Salvage Option: The study strongly suggests HIFU is a valuable, less invasive alternative for patients with residual or recurrent cervical cancer post-CRT, where traditional treatments are often problematic.
- High Disease Control: The high disease control rate (93.5%) indicates HIFU's effectiveness in managing local disease progression in this challenging patient group.
- Favorable Survival Outcomes: The median progression-free survival (17.0 months) and overall survival (24.5 months) are encouraging, demonstrating a tangible benefit for patients who have exhausted standard treatment options.
- Predictive Factors for Better Outcomes: Lesion size before treatment (≥1.40 cm) and a significant shrinkage rate (≥30%) after HIFU were associated with improved PFS and OS, suggesting these could be important markers for treatment success.
- Safety Profile: HIFU demonstrated a favorable safety profile with only minor, manageable complications (skin burns, abdominal pain, vaginal discharge), making it a well-tolerated option, even for older or physically compromised patients.
Key Results
- Objective Response Rate (ORR): 23.5% (36 patients achieved partial response).
- Disease Control Rate (DCR): 93.5% (107 patients had stable disease).
- Median Progression-Free Survival (mPFS): 17.0 months.
- Median Overall Survival (mOS): 24.5 months.
- Predictive Factors: Patients with lesions ≥1.40 cm before HIFU and a shrinkage rate ≥30% after treatment showed higher mPFS and mOS. Patients with lesions <1.00 cm after HIFU also had higher mPFS.
- Adverse Events: Limited to minor complications, with no grade C or higher adverse events reported.
Limitations and Future Work
The authors acknowledge that this was a single-center retrospective study, which introduces potential confounding factors and limits generalizability. They highlight the need for larger, prospective, multi-center randomized trials to further validate these findings and precisely identify patient subgroups that would benefit most from HIFU. Further research is also needed to explore the mechanistic underpinnings of HIFU's efficacy and to confirm the observation that initial treatment with surgery followed by radiotherapy or CRT might be associated with a higher risk of death compared to radical radiotherapy or CRT.
Summary updated